Kits for preparing 99mTc-MAA are available in the United States from only a single manufacturer; Jubilant DraxImage. The kits are delivered to nuclear pharmacies as lyophilized powders of non-radioactive ingredients sealed under nitrogen. A nuclear pharmacist adds anywhere from 50 - 100 mCi of Na[99mTcO4] to the reaction vial to make the final product, in the pH range of 3.8 to 8.0. After being allowed to react at room temperature for 15 minutes to ensure maximum labeling of the human albumin with 99mTc, the kit can then be diluted with sterile normal saline as needed.
Once prepared the product will have a turbid white appearance.
No less than 90% of MAA particles can be between 10 - 90 micrometres in size and no particles may exceed 150 micrometres due to the risk of pulmonary artery blockade.
No less than 90% of the radioactivity present in the product must be tagged to albumin particles. Thus, no more than 10% soluble impurities may be present.
Dosage and imaging
The typical adult dose for a lung imaging study is 40-150 Megabecquerels (1-4 mCi) (containing between 100,000 - 200,000 albumin particles). The particle burden should be lowered for most pediatric patients and lowered to 50,000 for infants. The use of more than 250,000 particles in a dose is controversial as little extra data is acquired from such scans while there is an increased risk of toxicity. Patients with pulmonary hypertension should be administered a minimum number of particles to achieve a lung scan (i.e. 60,000). In any patient by administering a greater quantity of particles than necessary for the diagnostic procedure increases the risks of toxicity.
Because of gravity effects, patients administered 99mTc MAA should be in the supine position to ensure as even a distribution of particles throughout the lungs as possible.
The total percentage of particles trapped in the lungs can be determined through a whole body scan after the administration of 99mTc MAA through the equation:
^MacDonald, A.; Burrell, S. (14 August 2008). "Infrequently Performed Studies in Nuclear Medicine: Part 1". Journal of Nuclear Medicine Technology. 36 (3): 132–143. doi:10.2967/jnmt.108.051383. PMID18703616.
^Fukuoka, Masamichi; Kobayashi, Tetsu; Satoh, Takemichi; Tanaka, Akira; Akiko, Kubodera (July 1993). "Studies of quality control of 99mTc-labelled macroaggregated albumin—Part 1. Aggregation of non-mercaptalbumin and its conformation". Nuclear Medicine and Biology. 20 (5): 643–648. doi:10.1016/0969-8051(93)90034-R. PMID8358350.
^Bajc, M.; Neilly, J. B.; Miniati, M.; Schuemichen, C.; Meignan, M.; Jonson, B. (27 June 2009). "EANM guidelines for ventilation/perfusion scintigraphy". European Journal of Nuclear Medicine and Molecular Imaging. 36 (8): 1356–1370. doi:10.1007/s00259-009-1170-5. PMID19562336.
^Parker, J. A.; Coleman, R. E.; Grady, E.; Royal, H. D.; Siegel, B. A.; Stabin, M. G.; Sostman, H. D.; Hilson, A. J. W. (26 January 2012). "SNM Practice Guideline for Lung Scintigraphy 4.0". Journal of Nuclear Medicine Technology. 40 (1): 57–65. doi:10.2967/jnmt.111.101386. PMID22282651.
^Zolle, Ilse (2007). "Monographs of 99mTc Pharmaceuticals". Technetium-99m pharmaceuticals (1st ed.). Berlin: Springer. p. 187. ISBN978-3-540-33989-2.
^Kaplan, W D; Come, S E; Takvorian, R W; Laffin, S M; Gelman, R S; Weiss, G R; Garnick, M B (November 1984). "Pulmonary uptake of technetium 99m macroaggregated albumin: a predictor of gastrointestinal toxicity during hepatic artery perfusion". Journal of Clinical Oncology. 2 (11): 1266–1269. doi:10.1200/JCO.19126.96.36.1996. PMID6491704.
Kowalsky, Richard J., Steven W. Falen. Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine. 2nd Edition.American Pharmacist Association: 2004.